Comparison of the treatment efficacies of HIFU, HIFU combined with GnRH-a, and HIFU combined with GnRH-a and LNG-IUS for adenomyosis: A systematic review and meta-analysis
AbstractTo compare the treatment efficacies of high-intensity focused ultrasound (HIFU), HIFU combined with gonadotrophin-releasing hormone agonist (GnRH-a), and HIFU combined with GnRH-a and levonorgestrel-releasing intrauterine system (LNG-IUS) for adenomyosis. We conducted a literature search in...
Gespeichert in:
| Veröffentlicht in: | Taiwanese journal of obstetrics & gynecology Jg. 62; H. 2; S. 226 - 238 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
China (Republic : 1949- )
Elsevier B.V
01.03.2023
Elsevier |
| Schlagworte: | |
| ISSN: | 1028-4559, 1875-6263, 1875-6263 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | AbstractTo compare the treatment efficacies of high-intensity focused ultrasound (HIFU), HIFU combined with gonadotrophin-releasing hormone agonist (GnRH-a), and HIFU combined with GnRH-a and levonorgestrel-releasing intrauterine system (LNG-IUS) for adenomyosis. We conducted a literature search in SCIENCE DIRECT, COCHRANE LIBRARY, WILLEY ONLINE LIBRARY, PUBMED, and TAYLOR FRANCIS. A total of 471 articles identified, 12 were included in a systematic review, and 11 of them deemed quantitively eligible included in the meta-analysis. The efficacies of the three treatment regimens were assessed using the dysmenorrhea and menstrual scores at 3, 6, 12, 24 months. Of the three regimens, HIFU combined with GnRH-a and LNG-IUS provides the best outcome. On dysmenorrhea score at 6 months there was significantly different higher heterogeneity with P < 0.00001 (I 2 = 100% WMD 21.44 [6.34, 36.53]) with statistical significance P = 0.005. At 12 months there was significantly different higher heterogeneity P < 0.00001 (I 2 = 100% WMD 23.47 [6.00, 40.94]) with statistically significant P < 0.008. At 24 months there was significantly different higher heterogeneity P < 0.0005 (I 2 = 92% WMD 6.05 [4.81, 7.30]) with statistical significance P < 0.00001. HIFU combined with GnRH-a and LNG-IUS on menstrual score at 3 months was significantly different higher heterogeneity with P < 0.00001 (I 2 = 100% WMD 56.23 [16.01, 96.45]) with statistical significance P = 0.006. At 6 months there was significantly different higher heterogeneity P < 0.00001 (I 2 = 99% WMD 93.86 [64.15, 123.57]) with statistical significance P < 0.00001. At 12 months there was significantly different higher heterogeneity P < 0.00001 (I 2 = 99% WMD 97.13 [67.81, 126.46]) with statistical significance P < 0.00001 compared to treatments with only HIFU and HIFU combined with GnRH-a. HIFU combined with GnRH-a and LNG-IUS treatment is more effective than only HIFU monotherapy and HIFU combined with GnRH-a. |
|---|---|
| AbstractList | To compare the treatment efficacies of high-intensity focused ultrasound (HIFU), HIFU combined with gonadotrophin-releasing hormone agonist (GnRH-a), and HIFU combined with GnRH-a and levonorgestrel-releasing intrauterine system (LNG-IUS) for adenomyosis. We conducted a literature search in SCIENCE DIRECT, COCHRANE LIBRARY, WILLEY ONLINE LIBRARY, PUBMED, and TAYLOR FRANCIS. A total of 471 articles identified, 12 were included in a systematic review, and 11 of them deemed quantitively eligible included in the meta-analysis. The efficacies of the three treatment regimens were assessed using the dysmenorrhea and menstrual scores at 3, 6, 12, 24 months. Of the three regimens, HIFU combined with GnRH-a and LNG-IUS provides the best outcome. On dysmenorrhea score at 6 months there was significantly different higher heterogeneity with P < 0.00001 (I
= 100% WMD 21.44 [6.34, 36.53]) with statistical significance P = 0.005. At 12 months there was significantly different higher heterogeneity P < 0.00001 (I
= 100% WMD 23.47 [6.00, 40.94]) with statistically significant P < 0.008. At 24 months there was significantly different higher heterogeneity P < 0.0005 (I
= 92% WMD 6.05 [4.81, 7.30]) with statistical significance P < 0.00001. HIFU combined with GnRH-a and LNG-IUS on menstrual score at 3 months was significantly different higher heterogeneity with P < 0.00001 (I
= 100% WMD 56.23 [16.01, 96.45]) with statistical significance P = 0.006. At 6 months there was significantly different higher heterogeneity P < 0.00001 (I
= 99% WMD 93.86 [64.15, 123.57]) with statistical significance P < 0.00001. At 12 months there was significantly different higher heterogeneity P < 0.00001 (I
= 99% WMD 97.13 [67.81, 126.46]) with statistical significance P < 0.00001 compared to treatments with only HIFU and HIFU combined with GnRH-a. HIFU combined with GnRH-a and LNG-IUS treatment is more effective than only HIFU monotherapy and HIFU combined with GnRH-a. To compare the treatment efficacies of high-intensity focused ultrasound (HIFU), HIFU combined with gonadotrophin-releasing hormone agonist (GnRH-a), and HIFU combined with GnRH-a and levonorgestrel-releasing intrauterine system (LNG-IUS) for adenomyosis. We conducted a literature search in SCIENCE DIRECT, COCHRANE LIBRARY, WILLEY ONLINE LIBRARY, PUBMED, and TAYLOR FRANCIS. A total of 471 articles identified, 12 were included in a systematic review, and 11 of them deemed quantitively eligible included in the meta-analysis. The efficacies of the three treatment regimens were assessed using the dysmenorrhea and menstrual scores at 3, 6, 12, 24 months. Of the three regimens, HIFU combined with GnRH-a and LNG-IUS provides the best outcome. On dysmenorrhea score at 6 months there was significantly different higher heterogeneity with P < 0.00001 (I2 = 100% WMD 21.44 [6.34, 36.53]) with statistical significance P = 0.005. At 12 months there was significantly different higher heterogeneity P < 0.00001 (I2 = 100% WMD 23.47 [6.00, 40.94]) with statistically significant P < 0.008. At 24 months there was significantly different higher heterogeneity P < 0.0005 (I2 = 92% WMD 6.05 [4.81, 7.30]) with statistical significance P < 0.00001. HIFU combined with GnRH-a and LNG-IUS on menstrual score at 3 months was significantly different higher heterogeneity with P < 0.00001 (I2 = 100% WMD 56.23 [16.01, 96.45]) with statistical significance P = 0.006. At 6 months there was significantly different higher heterogeneity P < 0.00001 (I2 = 99% WMD 93.86 [64.15, 123.57]) with statistical significance P < 0.00001. At 12 months there was significantly different higher heterogeneity P < 0.00001 (I2 = 99% WMD 97.13 [67.81, 126.46]) with statistical significance P < 0.00001 compared to treatments with only HIFU and HIFU combined with GnRH-a. HIFU combined with GnRH-a and LNG-IUS treatment is more effective than only HIFU monotherapy and HIFU combined with GnRH-a.To compare the treatment efficacies of high-intensity focused ultrasound (HIFU), HIFU combined with gonadotrophin-releasing hormone agonist (GnRH-a), and HIFU combined with GnRH-a and levonorgestrel-releasing intrauterine system (LNG-IUS) for adenomyosis. We conducted a literature search in SCIENCE DIRECT, COCHRANE LIBRARY, WILLEY ONLINE LIBRARY, PUBMED, and TAYLOR FRANCIS. A total of 471 articles identified, 12 were included in a systematic review, and 11 of them deemed quantitively eligible included in the meta-analysis. The efficacies of the three treatment regimens were assessed using the dysmenorrhea and menstrual scores at 3, 6, 12, 24 months. Of the three regimens, HIFU combined with GnRH-a and LNG-IUS provides the best outcome. On dysmenorrhea score at 6 months there was significantly different higher heterogeneity with P < 0.00001 (I2 = 100% WMD 21.44 [6.34, 36.53]) with statistical significance P = 0.005. At 12 months there was significantly different higher heterogeneity P < 0.00001 (I2 = 100% WMD 23.47 [6.00, 40.94]) with statistically significant P < 0.008. At 24 months there was significantly different higher heterogeneity P < 0.0005 (I2 = 92% WMD 6.05 [4.81, 7.30]) with statistical significance P < 0.00001. HIFU combined with GnRH-a and LNG-IUS on menstrual score at 3 months was significantly different higher heterogeneity with P < 0.00001 (I2 = 100% WMD 56.23 [16.01, 96.45]) with statistical significance P = 0.006. At 6 months there was significantly different higher heterogeneity P < 0.00001 (I2 = 99% WMD 93.86 [64.15, 123.57]) with statistical significance P < 0.00001. At 12 months there was significantly different higher heterogeneity P < 0.00001 (I2 = 99% WMD 97.13 [67.81, 126.46]) with statistical significance P < 0.00001 compared to treatments with only HIFU and HIFU combined with GnRH-a. HIFU combined with GnRH-a and LNG-IUS treatment is more effective than only HIFU monotherapy and HIFU combined with GnRH-a. AbstractTo compare the treatment efficacies of high-intensity focused ultrasound (HIFU), HIFU combined with gonadotrophin-releasing hormone agonist (GnRH-a), and HIFU combined with GnRH-a and levonorgestrel-releasing intrauterine system (LNG-IUS) for adenomyosis. We conducted a literature search in SCIENCE DIRECT, COCHRANE LIBRARY, WILLEY ONLINE LIBRARY, PUBMED, and TAYLOR FRANCIS. A total of 471 articles identified, 12 were included in a systematic review, and 11 of them deemed quantitively eligible included in the meta-analysis. The efficacies of the three treatment regimens were assessed using the dysmenorrhea and menstrual scores at 3, 6, 12, 24 months. Of the three regimens, HIFU combined with GnRH-a and LNG-IUS provides the best outcome. On dysmenorrhea score at 6 months there was significantly different higher heterogeneity with P < 0.00001 (I 2 = 100% WMD 21.44 [6.34, 36.53]) with statistical significance P = 0.005. At 12 months there was significantly different higher heterogeneity P < 0.00001 (I 2 = 100% WMD 23.47 [6.00, 40.94]) with statistically significant P < 0.008. At 24 months there was significantly different higher heterogeneity P < 0.0005 (I 2 = 92% WMD 6.05 [4.81, 7.30]) with statistical significance P < 0.00001. HIFU combined with GnRH-a and LNG-IUS on menstrual score at 3 months was significantly different higher heterogeneity with P < 0.00001 (I 2 = 100% WMD 56.23 [16.01, 96.45]) with statistical significance P = 0.006. At 6 months there was significantly different higher heterogeneity P < 0.00001 (I 2 = 99% WMD 93.86 [64.15, 123.57]) with statistical significance P < 0.00001. At 12 months there was significantly different higher heterogeneity P < 0.00001 (I 2 = 99% WMD 97.13 [67.81, 126.46]) with statistical significance P < 0.00001 compared to treatments with only HIFU and HIFU combined with GnRH-a. HIFU combined with GnRH-a and LNG-IUS treatment is more effective than only HIFU monotherapy and HIFU combined with GnRH-a. To compare the treatment efficacies of high-intensity focused ultrasound (HIFU), HIFU combined with gonadotrophin-releasing hormone agonist (GnRH-a), and HIFU combined with GnRH-a and levonorgestrel-releasing intrauterine system (LNG-IUS) for adenomyosis.We conducted a literature search in SCIENCE DIRECT, COCHRANE LIBRARY, WILLEY ONLINE LIBRARY, PUBMED, and TAYLOR FRANCIS. A total of 471 articles identified, 12 were included in a systematic review, and 11 of them deemed quantitively eligible included in the meta-analysis. The efficacies of the three treatment regimens were assessed using the dysmenorrhea and menstrual scores at 3, 6, 12, 24 months.Of the three regimens, HIFU combined with GnRH-a and LNG-IUS provides the best outcome. On dysmenorrhea score at 6 months there was significantly different higher heterogeneity with P < 0.00001 (I2 = 100% WMD 21.44 [6.34, 36.53]) with statistical significance P = 0.005. At 12 months there was significantly different higher heterogeneity P < 0.00001 (I2 = 100% WMD 23.47 [6.00, 40.94]) with statistically significant P < 0.008. At 24 months there was significantly different higher heterogeneity P < 0.0005 (I2 = 92% WMD 6.05 [4.81, 7.30]) with statistical significance P < 0.00001. HIFU combined with GnRH-a and LNG-IUS on menstrual score at 3 months was significantly different higher heterogeneity with P < 0.00001 (I2 = 100% WMD 56.23 [16.01, 96.45]) with statistical significance P = 0.006. At 6 months there was significantly different higher heterogeneity P < 0.00001 (I2 = 99% WMD 93.86 [64.15, 123.57]) with statistical significance P < 0.00001. At 12 months there was significantly different higher heterogeneity P < 0.00001 (I2 = 99% WMD 97.13 [67.81, 126.46]) with statistical significance P < 0.00001 compared to treatments with only HIFU and HIFU combined with GnRH-a.HIFU combined with GnRH-a and LNG-IUS treatment is more effective than only HIFU monotherapy and HIFU combined with GnRH-a. To compare the treatment efficacies of high-intensity focused ultrasound (HIFU), HIFU combined with gonadotrophin-releasing hormone agonist (GnRH-a), and HIFU combined with GnRH-a and levonorgestrel-releasing intrauterine system (LNG-IUS) for adenomyosis. We conducted a literature search in SCIENCE DIRECT, COCHRANE LIBRARY, WILLEY ONLINE LIBRARY, PUBMED, and TAYLOR FRANCIS. A total of 471 articles identified, 12 were included in a systematic review, and 11 of them deemed quantitively eligible included in the meta-analysis. The efficacies of the three treatment regimens were assessed using the dysmenorrhea and menstrual scores at 3, 6, 12, 24 months. Of the three regimens, HIFU combined with GnRH-a and LNG-IUS provides the best outcome. On dysmenorrhea score at 6 months there was significantly different higher heterogeneity with P < 0.00001 (I2 = 100% WMD 21.44 [6.34, 36.53]) with statistical significance P = 0.005. At 12 months there was significantly different higher heterogeneity P < 0.00001 (I2 = 100% WMD 23.47 [6.00, 40.94]) with statistically significant P < 0.008. At 24 months there was significantly different higher heterogeneity P < 0.0005 (I2 = 92% WMD 6.05 [4.81, 7.30]) with statistical significance P < 0.00001. HIFU combined with GnRH-a and LNG-IUS on menstrual score at 3 months was significantly different higher heterogeneity with P < 0.00001 (I2 = 100% WMD 56.23 [16.01, 96.45]) with statistical significance P = 0.006. At 6 months there was significantly different higher heterogeneity P < 0.00001 (I2 = 99% WMD 93.86 [64.15, 123.57]) with statistical significance P < 0.00001. At 12 months there was significantly different higher heterogeneity P < 0.00001 (I2 = 99% WMD 97.13 [67.81, 126.46]) with statistical significance P < 0.00001 compared to treatments with only HIFU and HIFU combined with GnRH-a. HIFU combined with GnRH-a and LNG-IUS treatment is more effective than only HIFU monotherapy and HIFU combined with GnRH-a. |
| Author | Wu, Trong-Neng Chuang, Linus T Shen, Jenta Jeng, Cherng-Jye Otgontuya, Altangerel |
| Author_xml | – sequence: 1 fullname: Otgontuya, Altangerel – sequence: 2 fullname: Jeng, Cherng-Jye – sequence: 3 fullname: Wu, Trong-Neng – sequence: 4 fullname: Chuang, Linus T – sequence: 5 fullname: Shen, Jenta |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36965889$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kt9u0zAUxiM0xP7AC3CBfMnFEmwncWyEkKaKtZUqkBi9tlznZHNI7GK7TH0mXhKn3biYxG5sy-f7Plvn_M6zE-ssZNlbgguCCfvQF7F3twXFlBaEFBiLF9kZ4U2dM8rKk3TGlOdVXYvT7DyEHuOqwRi_yk5LJljNuTjL_szcuFXeBGeR61C8AxQ9qDiCjQi6zmilDYSptlhery8PK9Ju3BgLLbo38Q7N7fdFri6Rsu3_y4fq6us8X65vUOc8Ui1YN-5dMOEjukJhHyKMKhqNPPw2cH8wjBBVrqwa9kn2OnvZqSHAm4f9Iltff_kxW-Srb_Pl7GqV65qSmDOo20p0FQBnBKpa0IbWjDW8YlSXDQUltGigIaqhjHYdbXXqCxCmRFtval1eZMtjbutUL7fejMrvpVNGHi6cv5XKp48OIGHDVEk7RhrGq4o3immyqVouqCCkI3XKen_M2nr3awchytEEDcOgLLhdkLQRJE2DE56k7x6ku80I7b-HH4eVBPwo0N6F4KGT2sTUMWejV2aQBMuJC9nLiQs5cSEJkYmLZKVPrI_pz5o-HU2Qmp1G4mVILFgNrfGgY-qGed7--YldD8YmoIafsIfQu51Pgw2SyEAlljcTrROstEyQUiLKv0NQ4_U |
| CitedBy_id | crossref_primary_10_1016_j_tjog_2023_04_005 crossref_primary_10_1002_jum_16623 crossref_primary_10_1016_j_cpsurg_2025_101898 crossref_primary_10_1080_02656736_2025_2501244 crossref_primary_10_1515_med_2024_0914 crossref_primary_10_1186_s12905_025_03619_0 crossref_primary_10_1097_GCO_0000000000000972 crossref_primary_10_1007_s00404_023_07340_x crossref_primary_10_1177_17455057241295593 crossref_primary_10_1016_j_ejogrb_2025_01_049 crossref_primary_10_3389_fmed_2025_1563888 crossref_primary_10_1016_j_tjog_2023_11_002 crossref_primary_10_1016_j_tjog_2024_02_004 crossref_primary_10_1186_s13063_025_08967_8 crossref_primary_10_2147_IJWH_S473005 crossref_primary_10_3390_jcm13164788 crossref_primary_10_1080_02656736_2025_2531028 crossref_primary_10_1111_1471_0528_18026 crossref_primary_10_1016_j_tjog_2023_04_001 |
| Cites_doi | 10.1016/j.ajog.2020.01.016 10.1080/02656736.2021.1886347 10.1080/02656736.2019.1595179 10.1016/j.fertnstert.2018.01.032 10.1097/RCT.0000000000001138 10.1111/1471-0528.14742 10.1080/02656736.2018.1440014 10.1080/02656736.2021.1967467 10.1016/j.tjog.2020.09.013 10.3109/02656736.2016.1149232 10.1080/14656566.2018.1462337 10.1111/1471-0528.14748 10.4103/ijri.IJRI_53_19 10.1080/02656736.2018.1509238 10.1016/j.ijgo.2013.08.022 10.3109/09513590903080928 10.1111/1471-0528.14736 10.1016/j.bpobgyn.2006.01.016 10.1080/02656736.2019.1679892 10.1016/j.fertnstert.2012.06.044 10.1080/02656736.2018.1516301 |
| ContentType | Journal Article |
| Copyright | 2023 Copyright © 2023. Published by Elsevier B.V. |
| Copyright_xml | – notice: 2023 – notice: Copyright © 2023. Published by Elsevier B.V. |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 DOA |
| DOI | 10.1016/j.tjog.2022.11.009 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1875-6263 |
| EndPage | 238 |
| ExternalDocumentID | oai_doaj_org_article_eb6a32f617684487a6c1b4d892911f15 36965889 10_1016_j_tjog_2022_11_009 S1028455923000219 1_s2_0_S1028455923000219 |
| Genre | Meta-Analysis Systematic Review Journal Article |
| GroupedDBID | --- --K .1- .FO .~1 0R~ 0SF 123 188 1B1 1P~ 1~. 1~5 2UF 2WC 4.4 457 4G. 53G 5VS 6I. 7-5 71M 8P~ 8RM AABNK AACTN AAEDW AAFTH AAIKJ AALRI AAQFI AAXUO ABBQC ABMAC ABWVN ABXDB ACGFS ACRPL ADMUD ADNMO ADVLN AEKER AENEX AEVXI AEXQZ AFCTW AFRHN AFTJW AGHFR AGYEJ AINHJ AITUG AJRQY AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ CEFSP CNMHZ CS3 DIK DU5 EBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FIRID FNPLU GBLVA GROUPED_DOAJ HVGLF HZ~ IHE IPNFZ J1W KQ8 M41 MO0 N9A NCXOZ O-L O9- OK1 OZT P-8 P-9 PC. Q38 RIG ROL RPZ SDF SDG SEL SES SSZ TUXDW UZ5 Z5R LCYCR 9DU AAYWO AAYXX ACVFH ADCNI AEUPX AFPUW AIGII AKBMS AKYEP CITATION ~HD CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c521t-6e5d49f4ee861e45927256678462c372ea9c97e71a7262ff2dc470e16a9d5b5c3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 20 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000966279100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1028-4559 1875-6263 |
| IngestDate | Fri Oct 03 12:51:09 EDT 2025 Fri Jul 11 11:55:47 EDT 2025 Mon Jul 21 05:57:38 EDT 2025 Sat Nov 29 07:09:31 EST 2025 Tue Nov 18 21:49:55 EST 2025 Fri Feb 23 02:36:35 EST 2024 Sun Feb 23 10:19:12 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | HIFU Treatment Efficiency GnRH-a Adenomyosis LNG-IUS |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2023. Published by Elsevier B.V. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c521t-6e5d49f4ee861e45927256678462c372ea9c97e71a7262ff2dc470e16a9d5b5c3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 ObjectType-Review-4 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://doaj.org/article/eb6a32f617684487a6c1b4d892911f15 |
| PMID | 36965889 |
| PQID | 2791369818 |
| PQPubID | 23479 |
| PageCount | 13 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_eb6a32f617684487a6c1b4d892911f15 proquest_miscellaneous_2791369818 pubmed_primary_36965889 crossref_citationtrail_10_1016_j_tjog_2022_11_009 crossref_primary_10_1016_j_tjog_2022_11_009 elsevier_sciencedirect_doi_10_1016_j_tjog_2022_11_009 elsevier_clinicalkeyesjournals_1_s2_0_S1028455923000219 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-03-01 |
| PublicationDateYYYYMMDD | 2023-03-01 |
| PublicationDate_xml | – month: 03 year: 2023 text: 2023-03-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | China (Republic : 1949- ) |
| PublicationPlace_xml | – name: China (Republic : 1949- ) |
| PublicationTitle | Taiwanese journal of obstetrics & gynecology |
| PublicationTitleAlternate | Taiwan J Obstet Gynecol |
| PublicationYear | 2023 |
| Publisher | Elsevier B.V Elsevier |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier |
| References | Keserci, Duc N (bib12) 2018; 35 Peng, Dai, Yu, Yang, Wen, Jin (bib18) 2021; 38 Gong, Yang, Shi, Liu, Wan, Zhang (bib8) 2016; 32 Guo, Xu, Ding, Wang, Gao (bib17) 2018; 35 Huang, Yu, Zou, Wang, Xing, Wang (bib13) 2017; 124 Jeng, Ou, Long, Chuang, Ker (bib6) 2020; 59 Ye, Deng, Zhu, Xue (bib22) 2016; 51 Grandi, Farulla, Sileo, Facchinetti (bib23) 2018; 19 Bergeron, Amant, Fereczy (bib1) 2006; 20 Zhang, Li, Xie, He, He, Zhang (bib21) 2014; 124 Yaping, Zhan, Haili, Lin, Guoyan (bib10) 2021; 45 Guo, Duan, Cheng, Zhang (bib9) 2017; 124 Li, Zhu, He, Jiang, Tian, Long (bib16) 2021; 38 Diallo, Raiga, Boujenah, Paulmier, Benoit, Caronne (bib25) 2017; 4 Haiyan, Lin, Shuhua, Wang (bib20) 2019; 36 Long, Chen, Xiong, Zou, Deng, Chen (bib11) 2015; 8 Zhang, Guo, Chen, Wang, Hong, Zang (bib15) 2018; 34 Dev, Gadddam, Kumar, Varradarajan (bib14) 2019; 29 Ying, Shu, Juan, Hing, Yi, Hua (bib26) 2018; 34 Gong, Yang, Shi, Liu, Wan, Zhang (bib4) 2016; 32 Zou, Chen, Wu, Xiong (bib7) 2017; 124 Yang, Zhang, Lin, Feng, Aili (bib19) 2021; 36 Schindler (bib24) 2009; 25 Yu, Schulze-Rath, Grafton, Hansen, Scholes, Deed (bib2) 2020; 223 Benagiano, Habiba, Brosesn (bib3) 2012; 98 Osada (bib5) 2018; 109 Dev (10.1016/j.tjog.2022.11.009_bib14) 2019; 29 Long (10.1016/j.tjog.2022.11.009_bib11) 2015; 8 Grandi (10.1016/j.tjog.2022.11.009_bib23) 2018; 19 Yu (10.1016/j.tjog.2022.11.009_bib2) 2020; 223 Gong (10.1016/j.tjog.2022.11.009_bib8) 2016; 32 Keserci (10.1016/j.tjog.2022.11.009_bib12) 2018; 35 Li (10.1016/j.tjog.2022.11.009_bib16) 2021; 38 Schindler (10.1016/j.tjog.2022.11.009_bib24) 2009; 25 Yaping (10.1016/j.tjog.2022.11.009_bib10) 2021; 45 Zhang (10.1016/j.tjog.2022.11.009_bib15) 2018; 34 Gong (10.1016/j.tjog.2022.11.009_bib4) 2016; 32 Jeng (10.1016/j.tjog.2022.11.009_bib6) 2020; 59 Guo (10.1016/j.tjog.2022.11.009_bib17) 2018; 35 Zhang (10.1016/j.tjog.2022.11.009_bib21) 2014; 124 Zou (10.1016/j.tjog.2022.11.009_bib7) 2017; 124 Peng (10.1016/j.tjog.2022.11.009_bib18) 2021; 38 Ye (10.1016/j.tjog.2022.11.009_bib22) 2016; 51 Yang (10.1016/j.tjog.2022.11.009_bib19) 2021; 36 Bergeron (10.1016/j.tjog.2022.11.009_bib1) 2006; 20 Guo (10.1016/j.tjog.2022.11.009_bib9) 2017; 124 Benagiano (10.1016/j.tjog.2022.11.009_bib3) 2012; 98 Diallo (10.1016/j.tjog.2022.11.009_bib25) 2017; 4 Huang (10.1016/j.tjog.2022.11.009_bib13) 2017; 124 Ying (10.1016/j.tjog.2022.11.009_bib26) 2018; 34 Haiyan (10.1016/j.tjog.2022.11.009_bib20) 2019; 36 Osada (10.1016/j.tjog.2022.11.009_bib5) 2018; 109 |
| References_xml | – volume: 35 start-page: 618 year: 2018 end-page: 628 ident: bib12 article-title: Magnetic resonance imaging features influencing high-intensity focused ultrasound ablation of adenomyosis with a nonperfused volume ratio of ≥90% as a measure of clinical treatment success: retrospective multivariate analysis publication-title: Int J Hyperthermia – volume: 38 start-page: 241 year: 2021 end-page: 247 ident: bib16 article-title: High-intensity focused ultrasound in the management of adenomyosis: long-term results from a single center publication-title: Int J Hyperthermia – volume: 34 start-page: 1289 year: 2018 end-page: 1297 ident: bib15 article-title: Effect of pre-treatment with gonadotropin-releasing hormone analogue GnRH-a on high-intensity focused ultrasound ablation for diffuse adenomyosis: a preliminary study publication-title: Int J Hyperthermia – volume: 38 start-page: 1271 year: 2021 end-page: 1275 ident: bib18 article-title: Clinical evaluation of HIFU combined with GnRH-a and LNG-IUS for adenomyosis patients who failed to respond to drug therapies: two-year follow-up results publication-title: Int J Hyperthermia – volume: 8 start-page: 11701 year: 2015 end-page: 11707 ident: bib11 article-title: Efficacy of high-intensity focused ultrasound ablation for adenomyosis therapy and sexual life quality publication-title: Int J Clin Exp Med – volume: 35 start-page: 497 year: 2018 end-page: 501 ident: bib17 article-title: High intensity focused ultrasound treatment of adenomyosis: a comparative study publication-title: Int J Hyperthermia – volume: 32 start-page: 496 year: 2016 end-page: 503 ident: bib8 article-title: Factors influencing the ablative efficiency of high intensity focused ultrasound (HIFU) treatment for adenomyosis: a retrospective study publication-title: Int J Hyperthermia – volume: 124 start-page: 7 year: 2017 end-page: 11 ident: bib9 article-title: Gonadotropin-releasing hormone agonist combined with high-intensity focused ultrasound ablation for adenomyosis: a clinical study publication-title: BJOG – volume: 59 start-page: 865 year: 2020 end-page: 871 ident: bib6 article-title: 500 cases of high-intensity focused ultrasound (HIFU) ablated uterine fibroids and adenomyosis publication-title: Taiwan J Obstet Gynecol – volume: 124 start-page: 46 year: 2017 end-page: 52 ident: bib13 article-title: The effect of exercise on high-intensity focused ultrasound treatment efficacy in uterine fibroids and adenomyosis: a retrospective study publication-title: BJOG – volume: 45 start-page: 224 year: 2021 end-page: 231 ident: bib10 article-title: High-intensity focused ultrasound combined with gonadotropin-releasing hormone agonist or levonorgestrel-releasing intrauterine system in treating dysmenorrhea of severe adenomyosis publication-title: J Comput Assisted Tomography – volume: 223 start-page: 94e1 year: 2020 end-page: 94e10 ident: bib2 article-title: Adenomyosis incidence, prevalence and treatment: United States population-based study 2006-2015 publication-title: Am J Obstet Gynecol – volume: 98 start-page: 572 year: 2012 end-page: 579 ident: bib3 article-title: The pathophysiology of uterine adenomyosis: as update publication-title: Fertil Steril – volume: 25 start-page: 765 year: 2009 end-page: 767 ident: bib24 article-title: The value of gonadotropin-releasing hormone-agonists together with other drugs for medical treatment and prevention publication-title: Gynecol Endocrinol – volume: 34 start-page: 1289 year: 2018 end-page: 1297 ident: bib26 article-title: Effect of pre-treatment with gonadotropin-releasing hormone analogue GnRH-a on high-intensity focused ultrasound ablation for diffuse adenomyosis: a preliminary study publication-title: Int J Hyperthermia – volume: 36 start-page: 485 year: 2021 end-page: 491 ident: bib19 article-title: Combined therapeutic effects of HIFU, GnRH-a and LNG-IUS for the treatment of severe adenomyosis publication-title: Int J Hyperthermia – volume: 32 start-page: 496 year: 2016 end-page: 503 ident: bib4 article-title: Factors influencing the ablative efficiency of high intensity focused ultrasound (HIFU) treatment of adenomyosis: a retrospective study publication-title: Int J Hyper – volume: 20 start-page: 511 year: 2006 end-page: 521 ident: bib1 article-title: Pathology and physiopathology of adenomyosis publication-title: Best Pract Res Clinical Obstet Gynaecol – volume: 36 start-page: 1178 year: 2019 end-page: 1184 ident: bib20 article-title: High-intensity focused ultrasound (HIFU) combined with gonadotropin-releasing hormone analogs (GnRHa) and levonorgestrel-releasing intrauterine system (LNG-IUS) for adenomyosis: a case series with long-term follow up publication-title: Int J Hyperthermia – volume: 124 start-page: 207 year: 2014 end-page: 211 ident: bib21 article-title: Effective ablation therapy of adenomyosis with ultrasound-guided high-intensity focused ultrasound publication-title: Int J Gynecol Obstet – volume: 51 start-page: 643 year: 2016 end-page: 649 ident: bib22 article-title: Clinical study of high intensity focused ultrasound ablation combined with GnRHa-a and LNG-US for the treatment of adenomyosis publication-title: China J Obstet Gynecol – volume: 124 start-page: 30 year: 2017 end-page: 35 ident: bib7 article-title: Pregnancy outcome in patients with uterine fibroids treated with ultrasound- guided high-intensity focused ultrasound publication-title: BJOG – volume: 29 start-page: 284 year: 2019 end-page: 288 ident: bib14 article-title: MR-guided focused ultrasound surgery: a novel non-invasive technique in the treatment of adenomyosis-18 month's follow-up of 12 cases publication-title: Indian J Radiology and Imaging – volume: 109 start-page: 406 year: 2018 end-page: 417 ident: bib5 article-title: Uterine adenomyosis and adenomyoma: the surgical approach publication-title: Fertil Steril – volume: 4 start-page: 53 year: 2017 end-page: 55 ident: bib25 article-title: A rare cause of antigen cancer elevation 125 (CA 125): a case of uterine adenomyosis publication-title: MOJ Women’s Health – volume: 19 start-page: 677 year: 2018 end-page: 686 ident: bib23 article-title: Levonorgestrel-releasing intra-uterine systems as female contraceptives publication-title: Expert Opin Pharmacother – volume: 223 start-page: 94e1 year: 2020 ident: 10.1016/j.tjog.2022.11.009_bib2 article-title: Adenomyosis incidence, prevalence and treatment: United States population-based study 2006-2015 publication-title: Am J Obstet Gynecol doi: 10.1016/j.ajog.2020.01.016 – volume: 38 start-page: 241 year: 2021 ident: 10.1016/j.tjog.2022.11.009_bib16 article-title: High-intensity focused ultrasound in the management of adenomyosis: long-term results from a single center publication-title: Int J Hyperthermia doi: 10.1080/02656736.2021.1886347 – volume: 36 start-page: 485 year: 2021 ident: 10.1016/j.tjog.2022.11.009_bib19 article-title: Combined therapeutic effects of HIFU, GnRH-a and LNG-IUS for the treatment of severe adenomyosis publication-title: Int J Hyperthermia doi: 10.1080/02656736.2019.1595179 – volume: 109 start-page: 406 year: 2018 ident: 10.1016/j.tjog.2022.11.009_bib5 article-title: Uterine adenomyosis and adenomyoma: the surgical approach publication-title: Fertil Steril doi: 10.1016/j.fertnstert.2018.01.032 – volume: 45 start-page: 224 year: 2021 ident: 10.1016/j.tjog.2022.11.009_bib10 article-title: High-intensity focused ultrasound combined with gonadotropin-releasing hormone agonist or levonorgestrel-releasing intrauterine system in treating dysmenorrhea of severe adenomyosis publication-title: J Comput Assisted Tomography doi: 10.1097/RCT.0000000000001138 – volume: 124 start-page: 30 issue: S3 year: 2017 ident: 10.1016/j.tjog.2022.11.009_bib7 article-title: Pregnancy outcome in patients with uterine fibroids treated with ultrasound- guided high-intensity focused ultrasound publication-title: BJOG doi: 10.1111/1471-0528.14742 – volume: 34 start-page: 1289 year: 2018 ident: 10.1016/j.tjog.2022.11.009_bib26 article-title: Effect of pre-treatment with gonadotropin-releasing hormone analogue GnRH-a on high-intensity focused ultrasound ablation for diffuse adenomyosis: a preliminary study publication-title: Int J Hyperthermia doi: 10.1080/02656736.2018.1440014 – volume: 38 start-page: 1271 issue: 1 year: 2021 ident: 10.1016/j.tjog.2022.11.009_bib18 article-title: Clinical evaluation of HIFU combined with GnRH-a and LNG-IUS for adenomyosis patients who failed to respond to drug therapies: two-year follow-up results publication-title: Int J Hyperthermia doi: 10.1080/02656736.2021.1967467 – volume: 59 start-page: 865 year: 2020 ident: 10.1016/j.tjog.2022.11.009_bib6 article-title: 500 cases of high-intensity focused ultrasound (HIFU) ablated uterine fibroids and adenomyosis publication-title: Taiwan J Obstet Gynecol doi: 10.1016/j.tjog.2020.09.013 – volume: 32 start-page: 496 year: 2016 ident: 10.1016/j.tjog.2022.11.009_bib8 article-title: Factors influencing the ablative efficiency of high intensity focused ultrasound (HIFU) treatment for adenomyosis: a retrospective study publication-title: Int J Hyperthermia doi: 10.3109/02656736.2016.1149232 – volume: 19 start-page: 677 year: 2018 ident: 10.1016/j.tjog.2022.11.009_bib23 article-title: Levonorgestrel-releasing intra-uterine systems as female contraceptives publication-title: Expert Opin Pharmacother doi: 10.1080/14656566.2018.1462337 – volume: 124 start-page: 46 issue: S3 year: 2017 ident: 10.1016/j.tjog.2022.11.009_bib13 article-title: The effect of exercise on high-intensity focused ultrasound treatment efficacy in uterine fibroids and adenomyosis: a retrospective study publication-title: BJOG doi: 10.1111/1471-0528.14748 – volume: 4 start-page: 53 year: 2017 ident: 10.1016/j.tjog.2022.11.009_bib25 article-title: A rare cause of antigen cancer elevation 125 (CA 125): a case of uterine adenomyosis publication-title: MOJ Women’s Health – volume: 8 start-page: 11701 issue: 7 year: 2015 ident: 10.1016/j.tjog.2022.11.009_bib11 article-title: Efficacy of high-intensity focused ultrasound ablation for adenomyosis therapy and sexual life quality publication-title: Int J Clin Exp Med – volume: 29 start-page: 284 year: 2019 ident: 10.1016/j.tjog.2022.11.009_bib14 article-title: MR-guided focused ultrasound surgery: a novel non-invasive technique in the treatment of adenomyosis-18 month's follow-up of 12 cases publication-title: Indian J Radiology and Imaging doi: 10.4103/ijri.IJRI_53_19 – volume: 35 start-page: 497 year: 2018 ident: 10.1016/j.tjog.2022.11.009_bib17 article-title: High intensity focused ultrasound treatment of adenomyosis: a comparative study publication-title: Int J Hyperthermia doi: 10.1080/02656736.2018.1509238 – volume: 124 start-page: 207 year: 2014 ident: 10.1016/j.tjog.2022.11.009_bib21 article-title: Effective ablation therapy of adenomyosis with ultrasound-guided high-intensity focused ultrasound publication-title: Int J Gynecol Obstet doi: 10.1016/j.ijgo.2013.08.022 – volume: 25 start-page: 765 year: 2009 ident: 10.1016/j.tjog.2022.11.009_bib24 article-title: The value of gonadotropin-releasing hormone-agonists together with other drugs for medical treatment and prevention publication-title: Gynecol Endocrinol doi: 10.3109/09513590903080928 – volume: 124 start-page: 7 issue: S3 year: 2017 ident: 10.1016/j.tjog.2022.11.009_bib9 article-title: Gonadotropin-releasing hormone agonist combined with high-intensity focused ultrasound ablation for adenomyosis: a clinical study publication-title: BJOG doi: 10.1111/1471-0528.14736 – volume: 20 start-page: 511 year: 2006 ident: 10.1016/j.tjog.2022.11.009_bib1 article-title: Pathology and physiopathology of adenomyosis publication-title: Best Pract Res Clinical Obstet Gynaecol doi: 10.1016/j.bpobgyn.2006.01.016 – volume: 36 start-page: 1178 year: 2019 ident: 10.1016/j.tjog.2022.11.009_bib20 article-title: High-intensity focused ultrasound (HIFU) combined with gonadotropin-releasing hormone analogs (GnRHa) and levonorgestrel-releasing intrauterine system (LNG-IUS) for adenomyosis: a case series with long-term follow up publication-title: Int J Hyperthermia doi: 10.1080/02656736.2019.1679892 – volume: 98 start-page: 572 year: 2012 ident: 10.1016/j.tjog.2022.11.009_bib3 article-title: The pathophysiology of uterine adenomyosis: as update publication-title: Fertil Steril doi: 10.1016/j.fertnstert.2012.06.044 – volume: 51 start-page: 643 year: 2016 ident: 10.1016/j.tjog.2022.11.009_bib22 article-title: Clinical study of high intensity focused ultrasound ablation combined with GnRHa-a and LNG-US for the treatment of adenomyosis publication-title: China J Obstet Gynecol – volume: 32 start-page: 496 year: 2016 ident: 10.1016/j.tjog.2022.11.009_bib4 article-title: Factors influencing the ablative efficiency of high intensity focused ultrasound (HIFU) treatment of adenomyosis: a retrospective study publication-title: Int J Hyper doi: 10.3109/02656736.2016.1149232 – volume: 34 start-page: 1289 year: 2018 ident: 10.1016/j.tjog.2022.11.009_bib15 article-title: Effect of pre-treatment with gonadotropin-releasing hormone analogue GnRH-a on high-intensity focused ultrasound ablation for diffuse adenomyosis: a preliminary study publication-title: Int J Hyperthermia doi: 10.1080/02656736.2018.1440014 – volume: 35 start-page: 618 year: 2018 ident: 10.1016/j.tjog.2022.11.009_bib12 article-title: Magnetic resonance imaging features influencing high-intensity focused ultrasound ablation of adenomyosis with a nonperfused volume ratio of ≥90% as a measure of clinical treatment success: retrospective multivariate analysis publication-title: Int J Hyperthermia doi: 10.1080/02656736.2018.1516301 |
| SSID | ssj0047000 ssib060475427 |
| Score | 2.383575 |
| SecondaryResourceType | review_article |
| Snippet | AbstractTo compare the treatment efficacies of high-intensity focused ultrasound (HIFU), HIFU combined with gonadotrophin-releasing hormone agonist (GnRH-a),... To compare the treatment efficacies of high-intensity focused ultrasound (HIFU), HIFU combined with gonadotrophin-releasing hormone agonist (GnRH-a), and HIFU... |
| SourceID | doaj proquest pubmed crossref elsevier |
| SourceType | Open Website Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 226 |
| SubjectTerms | Adenomyosis Adenomyosis - surgery Dysmenorrhea - therapy Efficiency Female GnRH-a Gonadotropin-Releasing Hormone HIFU Humans Internal Medicine Intrauterine Devices, Medicated Levonorgestrel - therapeutic use LNG-IUS Obstetrics and Gynecology Treatment Treatment Outcome |
| Title | Comparison of the treatment efficacies of HIFU, HIFU combined with GnRH-a, and HIFU combined with GnRH-a and LNG-IUS for adenomyosis: A systematic review and meta-analysis |
| URI | https://www.clinicalkey.es/playcontent/1-s2.0-S1028455923000219 https://dx.doi.org/10.1016/j.tjog.2022.11.009 https://www.ncbi.nlm.nih.gov/pubmed/36965889 https://www.proquest.com/docview/2791369818 https://doaj.org/article/eb6a32f617684487a6c1b4d892911f15 |
| Volume | 62 |
| WOSCitedRecordID | wos000966279100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1875-6263 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0047000 issn: 1028-4559 databaseCode: DOA dateStart: 20040101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELWgQohLxTdboDISNxpInNiOuZWK7Vaiq4qy0t4sx5mgrdqkarZI_Kb-yc7ESSiHlguXHNax1slMZt5Lxm8Ye4_M3wvpkOS41EeZSSEqYgWRloUqZaZJoKVrNqHn83y5NEc3Wn1RTViQBw437hMUyqWiwkSrcqQS2imfFFmZY1pPkqrbXi5ibQYyFWJwpuM46BDQuyMEzf12mVDZtT5pfiIzFOIj6XdSKeKNlNQp9_-VmW5Dnl0Gmj5mmz105LthyU_YPaifsoeH_cfxZ-xqb-wpyJuKI7LjYxk5B5KKcPggtzQ2O5gudrojR49DcgwlpzeyfL_-PovcDnd1eftwN_ptvh8dLI45gl7uMHg1Z7-bdtV-5rv8jzo0DztjuglnsHaR6zVQnrPF9OuPvVnU92KIPLU8iBTIMjNVBpCrBDJphEawhJkuU8KnWoAz3mjQidNCiaoSpUcjQKKcKWUhffqCbdRNDa8YLySoVOfSO-LlpXJZnAKyQEW9AgtTTlgymMP6Xqic-mWc2qEi7cSSCS2ZEBmMRRNO2IdxznmQ6bjz7C9k5fFMktjufkDHs73j2X853oTpwUfssIsV4y60fRBobWJbYWN7TF5ITohsjyAV_r0cZ_Y4J-AXXMTqzmW_G1zRYhCgLzuuhuaytUKbJFUGwdeEvQw-Ol4cNWyUeW62_sdFv2aPcEFpKMJ7wzbWF5fwlj3wv9ar9mKb3dfLfLt7EvE4Pzq8Bv4tMUo |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+the+treatment+efficacies+of+HIFU%2C+HIFU+combined+with+GnRH-a%2C+and+HIFU+combined+with+GnRH-a+and+LNG-IUS+for+adenomyosis%3A+A+systematic+review+and+meta-analysis&rft.jtitle=Taiwanese+journal+of+obstetrics+%26+gynecology&rft.au=Altangerel+Otgontuya&rft.au=Cherng-Jye+Jeng&rft.au=Trong-Neng+Wu&rft.au=Linus+T.+Chuang&rft.date=2023-03-01&rft.pub=Elsevier&rft.issn=1028-4559&rft.volume=62&rft.issue=2&rft.spage=226&rft.epage=238&rft_id=info:doi/10.1016%2Fj.tjog.2022.11.009&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_eb6a32f617684487a6c1b4d892911f15 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F10284559%2FS1028455923X00035%2Fcov150h.gif |